Canadian society of nephrology commentary on the 2012 KDIGO clinical practice guideline for glomerulonephritis: Management of glomerulonephritis in adults

American Journal of Kidney Diseases

Volumn 63, Issue 3, 2014, Pages 363-377

  Cybulsky, Andrey V ^a   Walsh, Michael ^b   Knoll, Greg ^c   Hladunewich, Michelle ^d   Bargman, Joanne ^d   Reich, Heather ^d   Humar, Atul ^e   Samuel, Susan ^e   Bitzan, Martin ^f   Zappitelli, Michael ^f   Dart, Allison ^g   Mammen, Cherry ^h   Pinsk, Maury ^e   Muirhead, Norman ⁱ  

^a MCGILL UNIVERSITY   (Canada)

^b MCMASTER UNIVERSITY   (Canada)

^c UNIVERSITY OF OTTAWA   (Canada)

^d UNIVERSITY OF TORONTO   (Canada)

^e UNIVERSITY OF ALBERTA   (Canada)

^f MONTREAL CHILDREN S HOSPITAL   (Canada)

^g UNIVERSITY OF MANITOBA   (Canada)

^h UNIVERSITY OF BRITISH COLUMBIA   (Canada)

ⁱ UNIVERSITY OF WESTERN ONTARIO   (Canada)

Author keywords

Canadian Society of Nephrology (CSN); Clinical practice guideline implementation; glomerulonephritis; KDIGO (Kidney Disease: Improving Global Outcomes); nephrotic syndrome

Indexed keywords

ACUTE KIDNEY FAILURE; ADULT; ANAPHYLACTOID PURPURA; BLOOD PRESSURE REGULATION; CANADA; CLINICAL PRACTICE; CONSERVATIVE TREATMENT; CONTROLLED CLINICAL TRIAL (TOPIC); CORONARY ARTERY DISEASE; CORTICOSTEROID THERAPY; CREATININE BLOOD LEVEL; DISEASE ACTIVITY; END STAGE RENAL DISEASE; FOCAL GLOMERULOSCLEROSIS; GLOMERULONEPHRITIS; GLOMERULOPATHY; GLOMERULUS FILTRATION RATE; HEALTH CARE; HEALTH CARE COST; HEPATITIS B VIRUS; HEPATITIS C VIRUS; HUMAN; HYPERLIPIDEMIA; IMMUNOGLOBULIN A NEPHROPATHY; IMMUNOSUPPRESSIVE TREATMENT; KIDNEY BIOPSY; KIDNEY FUNCTION; LUPUS ERYTHEMATOSUS NEPHRITIS; MAINTENANCE THERAPY; MEDICAL SOCIETY; MEMBRANOPROLIFERATIVE GLOMERULONEPHRITIS; MEMBRANOUS GLOMERULONEPHRITIS; MICROALBUMINURIA; NEPHROLOGIST; NEPHROLOGY; NEPHROTIC SYNDROME; OUTCOME ASSESSMENT; PRACTICE GUIDELINE; PROTEIN URINE LEVEL; PROTEINURIA; RANDOMIZED CONTROLLED TRIAL (TOPIC); RELAPSE; REMISSION; REVIEW; RISK REDUCTION; TREATMENT DURATION; TREATMENT FAILURE; TREATMENT RESPONSE;

CANADIAN SOCIETY OF NEPHROLOGY (CSN); CLINICAL PRACTICE GUIDELINE IMPLEMENTATION; GLOMERULONEPHRITIS; KDIGO (KIDNEY DISEASE: IMPROVING GLOBAL OUTCOMES); NEPHROTIC SYNDROME;

ADULT; CANADA; DISEASE MANAGEMENT; GLOMERULONEPHRITIS; HUMANS; NEPHROLOGY; PRACTICE GUIDELINES AS TOPIC; SOCIETIES, MEDICAL;

EID: 84894483401     PISSN: 02726386     EISSN: 15236838     Source Type: Journal    
DOI: 10.1053/j.ajkd.2013.12.001     Document Type: Article

References (86)

1. Kidney Disease: Improving Global Outcomes (KDIGO) CKD-MBD Work Group KDIGO Clinical Practice Guideline for the Diagnosis, Evaluation, Prevention and Treatment of Chronic Kidney Disease-Metabolic Bone Disorder (CKD-MBD) Kidney Int Suppl 113 2009 S1 S130
2. Kidney Disease: Improving Global Outcomes (KDIGO) Transplant Work Group KDIGO Clinical Practice Guideline for the Care of Renal Transplant Recipients Am J Transplant 9 suppl 3 2009 S1 S155
3. Kidney Disease: Improving Global Outcomes (KDIGO) Blood Pressure Work Group KDIGO Clinical Practice Guideline for the Management of Blood Pressure in Chronic Kidney Disease Kidney Int Suppl 2 5 2012 337 414
4. Kidney Disease: Improving Global Outcomes (KDIGO) Acute Kidney Injury Work Group KDIGO Clinical Practice Guideline for Acute Kidney Injury Kidney Int Suppl 2 1 2012 1 138
5. Kidney Disease: Improving Global Outcomes (KDIGO) Anemia Work Group Clinical Practice Guideline for Anemia in Chronic Kidney Disease Kidney Int Suppl 2 4 2012 279 335
6. Kidney Disease: Improving Global Outcomes (KDIGO) KDIGO Clinical Practice Guidelines for the Prevention, Diagnosis, Evaluation and Treatment of Hepatitis C in Chronic Kidney Disease Kidney Int Suppl 109 2008 S1 S99
7. Kidney Disease: Improving Global Outcomes (KDIGO) Glomerulonephritis Work Group KDIGO Clinical Practice Guideline for Glomerulonephritis Kidney Int Suppl 2 2 2012 139 274
8. S. Samuel, M. Bitzan, and M. Zappitelli et al. Canadian Society of Nephrology Commentary on the 2012 KDIGO Clinical Practice Guideline for Glomerulonephritis: management of nephrotic syndrome in children Am J Kidney Dis 63 3 2014 354 362
9. S.C. Palmer, K. Nand, and G.F. Strippoli Interventions for minimal change disease in adults with nephrotic syndrome Cochrane Database Syst Rev 1 2008 CD001537
10. D.C. Cattran, G.B. Appel, and L.A. Hebert et al. A randomized trial of cyclosporine in patients with steroid-resistant focal segmental glomerulosclerosis. North America Nephrotic Syndrome Study Group Kidney Int 56 6 1999 2220 2226
11. D.S. Gipson, H. Trachtman, and F.J. Kaskel et al. Clinical trial of focal segmental glomerulosclerosis in children and young adults Kidney Int 80 8 2011 868 878
12. E.T. McCarthy, M. Sharma, and V.J. Savin Circulating permeability factors in idiopathic nephrotic syndrome and focal segmental glomerulosclerosis Clin J Am Soc Nephrol 5 2010 2115 2121
13. C. Wei, S. El Hindi, and J. Li et al. Circulating urokinase receptor as a cause of focal segmental glomerulosclerosis Nat Med 17 2011 952 960
14. P. Ronco, and H. Debiec Pathogenesis of membranous nephropathy: recent advances and future challenges Nat Rev Nephrol 8 2012 203 213
15. D.C. Cattran, Y. Pei, C.M. Greenwood, C. Ponticelli, P. Passerini, and E. Honkanen Validation of a predictive model of idiopathic membranous nephropathy: its clinical and research implications Kidney Int 51 1997 901 907
16. N. Polanco, E. Gutierrez, A. Covarsi Grupo de Estudio de las Enfermedades Glomerulares de la Sociedad Espanola de Nefrologia (GLOSEN) Spontaneous remission of nephrotic syndrome in idiopathic membranous nephropathy J Am Soc Nephrol 21 2010 697 704
17. E.P. McQuarrie, C.M. Stirling, and C.C. Geddes Idiopathic membranous nephropathy and nephrotic syndrome: outcome in the era of evidence-based therapy Nephrol Dial Transplant 27 2012 235 242
18. A. Howman, T.L. Chapman, and M.M. Langdon et al. Immunosuppression for progressive membranous nephropathy: A UK randomised controlled trial Lancet 381 9868 2013 744 751
19. S. Sethi, and F.C. Fervenza Membranoproliferative glomerulonephritis - a new look at an old entity N Engl J Med 366 2012 1119 1131
20. S. Sethi, C.M. Nester, and R.J. Smith Membranoproliferative glomerulonephritis and C3 glomerulopathy: resolving the confusion Kidney Int 81 2012 434 441
21. G.B. Appel, H.T. Cook, and G. Hageman et al. Membranoproliferative glomerulonephritis type II (dense deposit disease): An update J Am Soc Nephrol 16 2005 1392 1403
22. S.H. Nasr, A. Satoskar, and G.S. Markowitz et al. Proliferative glomerulonephritis with monoclonal IgG deposits J Am Soc Nephrol 20 2009 2055 2064
23. F. Fakhouri, V. Fremeaux-Bacchi, L.H. Noel, H.T. Cook, and M.C. Pickering C3 glomerulopathy: A new classification Nat Rev Nephrol 6 2010 494 499
24. A.S. Bomback, R.J. Smith, and G.R. Barile et al. Eculizumab for dense deposit disease and C3 glomerulonephritis Clin J Am Soc Nephrol 7 2012 748 756
25. M. Sherman, S. Shafran, and K. Burak et al. Management of chronic hepatitis B: consensus guidelines Can J Gastroenterol 21 suppl C 2007 5C 24C
26. M.G. Ghany, D.R. Nelson, D.B. Strader, D.L. Thomas, L.B. Seeff American Association for Study of Liver Diseases An update on treatment of genotype 1 chronic hepatitis C virus infection: 2011 practice guideline by the American Association for the Study of Liver Diseases Hepatology 54 4 2011 1433 1444
27. P. Ramachandran, A. Fraser, and K. Agarwal et al. UK consensus guidelines for the use of the protease inhibitors boceprevir and telaprevir in genotype 1 chronic hepatitis C infected patients Aliment Pharmacol Ther 35 6 2012 647 662
28. M. Sherman, S. Shafran, and K. Burak et al. Management of chronic hepatitis C: consensus guidelines Can J Gastroenterol 21 suppl C 2007 25C 34C
29. Montaner J; for the BC Centre for Excellence in HIV/AIDS. Antiretroviral treatment of adult HIV infection. http://www.cfenet.ubc.ca/sites/default/files/ uploads/BCCfE%20Adult%20Therapeutic%20Guidelines-Jan2011.pdf. Accessed June 7, 2012.
30. Working Group of the International IgA Nephropathy Network and the Renal Pathology Society D.C. Cattran, R. Coppo, and H.T. Cook et al. The Oxford classification of IgA nephropathy: rationale, clinicopathological correlations, and classification Kidney Int 76 5 2009 534 545
31. Working Group of the International IgA Nephropathy Network and the Renal Pathology Society I.S. Roberts, H.T. Cook, and S. Troyanov et al. The Oxford classification of IgA nephropathy: pathology definitions, correlations, and reproducibility Kidney Int 76 5 2009 546 556
32. A.M. Herzenberg, A.B. Fogo, and H.N. Reich et al. Validation of the Oxford classification of IgA nephropathy Kidney Int 80 3 2011 310 317
33. R. Katafuchi, T. Ninomiya, M. Nagata, K. Mitsuiki, and H. Hirakata Validation study of Oxford classification of IgA nephropathy: the significance of extracapillary proliferation Clin J Am Soc Nephrol 6 12 2011 2806 2813
34. S.F. Shi, S.X. Wang, and L. Jiang et al. Pathologic predictors of renal outcome and therapeutic efficacy in IgA nephropathy: validation of the Oxford classification Clin J Am Soc Nephrol 6 9 2011 2175 2184
35. Y. Shima, K. Nakanishi, and T. Hama et al. Validity of the Oxford classification of IgA nephropathy in children Pediatr Nephrol 27 5 2012 783 792
36. R. Yamamoto, and Y. Nagasawa Pathology: Oxford IgA nephropathy classification: valid for children? Nat Rev Nephrol 6 11 2010 638 639
37. H.N. Reich, S. Troyanov, J.W. Scholey, and D.C. Cattran Toronto Glomerulonephritis Registry. Remission of proteinuria improves prognosis in IgA nephropathy J Am Soc Nephrol 18 12 2007 3177 3183
38. A. Upadhyay, A. Earley, S.M. Haynes, and K. Uhlig Systematic review: blood pressure target in chronic kidney disease and proteinuria as an effect modifier Ann Intern Med 154 8 2011 541 548
39. M.R. Weir Microalbuminuria and cardiovascular disease Clin J Am Soc Nephrol 2 3 2007 581 590
40. J. Lv, H. Zhang, and Y. Chen et al. Combination therapy of prednisone and ACE inhibitor versus ACE-inhibitor therapy alone in patients with IgA nephropathy: A randomized controlled trial Am J Kidney Dis 53 1 2009 26 32
41. C. Manno, D.D. Torres, M. Rossini, F. Pesce, and F.P. Schena Randomized controlled clinical trial of corticosteroids plus ACE-inhibitors with long-term follow-up in proteinuric IgA nephropathy Nephrol Dial Transplant 24 12 2009 3694 3701
42. J. Lv, D. Xu, and V. Perkovic et al. Corticosteroid therapy in IgA nephropathy J Am Soc Nephrol 23 6 2012 1108 1116
43. C. Pozzi, S. Andrulli, and L. Del Vecchio et al. Corticosteroid effectiveness in IgA nephropathy: long-term results of a randomized, controlled trial J Am Soc Nephrol 15 1 2004 157 163
44. C. Pozzi, S. Andrulli, and A. Pani et al. Addition of azathioprine to corticosteroids does not benefit patients with IgA nephropathy J Am Soc Nephrol 21 10 2010 1783 1790
45. G. Frisch, J. Lin, and J. Rosenstock et al. Mycophenolate mofetil (MMF) vs placebo in patients with moderately advanced IgA nephropathy: A double-blind randomized controlled trial Nephrol Dial Transplant 20 10 2005 2139 2145
46. B.D. Maes, R. Oyen, and K. Claes et al. Mycophenolate mofetil in IgA nephropathy: results of a 3-year prospective placebo-controlled randomized study Kidney Int 65 5 2004 1842 1849
47. S.C. Tang, A.W. Tang, S.S. Wong, J.C. Leung, Y.W. Ho, and K.N. Lai Long-term study of mycophenolate mofetil treatment in IgA nephropathy Kidney Int 77 6 2010 543 549
48. J. Lv, H. Zhang, Z. Cui, T. Su, Y. Zhang, and H. Wang Delayed severe pneumonia in mycophenolate mofetil-treated patients with IgA nephropathy Nephrol Dial Transplant 23 9 2008 2868 2872
49. T.F. Hiemstra, M. Walsh, A. Mahr European Vasculitis Study Group (EUVAS) Mycophenolate mofetil vs azathioprine for remission maintenance in antineutrophil cytoplasmic antibody-associated vasculitis: A randomized controlled trial JAMA 304 21 2010 2381 2388
50. P.M. Ferraro, G.F. Ferraccioli, G. Gambaro, P. Fulignati, and S. Costanzi Combined treatment with renin-angiotensin system blockers and polyunsaturated fatty acids in proteinuric IgA nephropathy: A randomized controlled trial Nephrol Dial Transplant 24 1 2009 156 160
51. T. Pankhurst, J. Lepenies, P. Nightingale, A.J. Howie, D. Adu, and L. Harper Vasculitic IgA nephropathy: prognosis and outcome Nephron Clin Pract 112 1 2009 c16 c24
52. J.A. Tumlin, V. Lohavichan, and R. Hennigar Crescentic, proliferative IgA nephropathy: clinical and histological response to methylprednisolone and intravenous cyclophosphamide Nephrol Dial Transplant 18 7 2003 1321 1329
53. J. Weening, V. D'Agati, and M. Schwartz et al. The classification of glomerulonephritis in systemic lupus erythematosus revisited J Am Soc Nephrol 15 2 2004 241 250
54. Y. Chen, S. Korbet, R. Katz, and M. Schwartz Value of a complete or partial remission in severe lupus nephritis Clin J Am Soc Nephrol 3 1 2008 46 53
55. H. Reich, D. Gladman, and M. Urowitz et al. Persistent proteinuria and dyslipidemia increase the risk of progressive chronic kidney disease in lupus erythematosus Kidney Int 79 8 2011 914 920
56. J. Donadio, K. Holley, R. Ferguson, and D. Illstrup Treatment of diffuse proliferative lupus nephritis with prednisone and combined prednisone and cyclophosphamide N Engl J Med 299 1978 1151 1155
57. M. Walsh, D. Jayne, L. Moist, M. Tonelli, N. Pannu, and B. Manns Practice pattern variation in oral glucocorticoid therapy after induction of response in proliferative lupus nephritis Lupus 19 2010 628 633
58. F. Houssiau, C. Vasconcelos, and D. D'Cruz et al. Immunosuppressive therapy in lupus nephritis: the Euro-Lupus nephritis trial, a randomized trial of low-dose versus high-dose intravenous cyclophosphamide Arthritis Rheum 46 2002 2121 2131
59. H. Austin, H. Klippel, and J. Balow et al. Therapy of lupus nephritis. Controlled trial of prednisone and cytotoxic drugs N Engl J Med 314 1986 614 619
60. M. Walsh, N. Solomons, L. Lisk, and J.R. Jayne Mycophenolate mofetil or intravenous cyclophosphamide for lupus nephritis with poor kidney function. A subgroup analysis of the Aspreva Lupus Management Study Am J Kidney Dis 61 5 2013 710 715
61. C. Grootscholten, G. Ligtenberg, and E. Hagen et al. Azathioprine/ methylprednisolone versus cyclophosphamide in proliferative lupus nephritis. A randomized controlled trial Kidney Int 70 2006 732 742
62. C. Grootscholten, M. Bajema, and S. Florquin et al. Treatment with cyclophosphamide delays the progression of chronic lesions more effectively than does treatment with azathioprine plus methylprednisolone in patients with proliferative lupus nephritis Arthritis Rheum 56 2007 924 937
63. S. Arends, C. Grootscholten, R. Derksen on behalf of the Dutch Working Party on Systemic Lupus Erythematosus Long term follow-up of a randomized controlled trial of azathioprine/methylprednisolone versus cyclophosphamide in patients with proliferative lupus nephritis Ann Rheum Dis 71 6 2012 966 973
64. G. Contreras, V. Pardo, and B. Leclerq et al. Sequential therapies for proliferative lupus nephritis N Engl J Med 350 2004 971 980
65. F. Houssiau, D. D'Cruz, and S. Sangle et al. Azathioprine versus mycophenolate mofetil for long-term immunosuppression in lupus nephritis: results from the MAINTAIN Nephritis trial Ann Rheum Dis 69 2010 2083 2089
66. M. Dooley, D. Jayne, and E. Ginzler et al. Mycophenolate versus azathioprine as maintenance therapy for lupus nephritis N Engl J Med 365 2011 1886 1895
67. H. Austin, G. Ilei, M. Braun, and J. Balow Randomized, controlled trial of prednisone, cyclophosphamide and cyclosporine in lupus membranous nephropathy J Am Soc Nephrol 20 2009 901 911
68. Collaborative Study Group A controlled study of short-term prednisone treatment in adults with membranous nephropathy - collaborative study of the adult idiopathic nephrotic syndrome N Engl J Med 301 24 1979 1301 1306
69. J. Swan, D. Riche, K. Riche, and K. Majithia Systematic review and meta-analysis of immunosuppressant clinical trials in membranous lupus nephritis J Investig Med 59 2011 246 258
70. G. Moroni, S. Quaglini, and L. Gravellone et al. Membranous nephropathy in systemic lupus erythematosus: long-term outcome and prognostic factors of 103 patients Semin Arthritis Rheum 41 2012 642 651
71. M. Petri, D. Howard, and J. Repke Frequency of lupus flare in pregnancy. The Hopkins Lupus Pregnancy Center experience Arthritis Rheum 34 12 1991 1538 1545
72. K. De Groot, N. Rasmussen, and P.A. Bacon et al. Randomized trial of cyclophosphamide versus methotrexate for induction of remission in early systemic antineutrophil cytoplasmic antibody-associated vasculitis Arthritis Rheum 52 2005 2461 2469
73. M. Faurschou, K. Westman, and N. Rasmussen et al. Long-term outcome of a clinical trial comparing methotrexate to cyclophosphamide for remission induction of early systemic ANCA-associated vasculitis Arthritis Rheum 64 10 2012 3472 3477
74. R.B. Jones, J.W. Tervaert, and T. Hauser et al. Rituximab versus cyclophosphamide in ANCA-associated renal vasculitis N Engl J Med 363 2010 211 220
75. J.H. Stone, P.A. Merkel, and R. Spiera et al. Rituximab versus cyclophosphamide for ANCA-associated vasculitis N Engl J Med 363 2010 221 232
76. M. Walsh, F. Catapano, and W. Szpirt et al. Plasma exchange for renal vasculitis and idiopathic rapidly progressive glomerulonephritis: A meta-analysis Am J Kidney Dis 57 2011 566 574
77. M.A. Little, P. Nightingale, and C.A. Verburgh et al. Early mortality in systemic vasculitis: relative contribution of adverse events and active vasculitis Ann Rheum Dis 69 2010 1036 1043
78. D. Jayne, N. Rasmussen, and K. Andrassy et al. A randomized trial of maintenance therapy for vasculitis associated with antineutrophil cytoplasmic autoantibodies N Engl J Med 349 2003 36 44
79. C. Pagnoux, A. Mahr, and M.A. Hamidou et al. Azathioprine or methotrexate maintenance for ANCA-associated vasculitis N Engl J Med 359 2008 2790 2803
80. T.F. Hiemstra, M. Walsh, and A. Mahr et al. Mycophenolate mofetil vs azathioprine for remission maintenance in antineutrophil cytoplasmic antibody-associated vasculitis: A randomized controlled trial JAMA 304 2010 2381 2388
81. M. Walsh, P.A. Merkel, A. Mahr, and D. Jayne Effects of duration of glucocorticoid therapy on relapse rate in antineutrophil cytoplasmic antibody-associated vasculitis: A meta-analysis Arthritis Care Res (Hoboken) 62 2010 1166 1173
82. J.G. McGregor, S.L. Hogan, Y. Hu, C.E. Jennette, R.J. Falk, and P.H. Nachman Glucocorticoids and relapse and infection rates in anti-neutrophil cytoplasmic antibody disease Clin J Am Soc Nephrol 7 2012 240 247
83. M. Walsh, and D. Jayne Rituximab in the treatment of anti-neutrophil cytoplasm antibody associated vasculitis and systemic lupus erythematosus: past, present and future Kidney Int 72 2007 676 682
84. M. Walsh, A. Chaudry, and D. Jayne Long-term follow-up of relapsing/refractory anti-nuclear cytoplasmic antibody associated vasculitis treated with the lymphocyte depleting antibody alemtuzumab (CAMPATH-1H) Ann Rheum Dis 67 9 2008 1322 1327
85. O. Flossmann, B. Baslund, and A. Bruchfeld et al. Deoxyspergualin in relapsing and refractory Wegener's granulomatosis Ann Rheum Dis 68 2009 1125 1130
86. R.A. de Lind van Wijngaarden, H.A. Hauer, and R. Wolterbeek et al. Clinical and histologic determinants of renal outcome in ANCA-associated vasculitis: A prospective analysis of 100 patients with severe renal involvement J Am Soc Nephrol 17 2006 2264 2274